Format

Send to

Choose Destination
Mol Imaging Biol. 2020 Feb;22(1):47-65. doi: 10.1007/s11307-019-01361-2.

Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria.

Author information

1
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
2
QIMP Team, Center for Medical Physics and Biomedical Engineering, General Hospital Vienna, Medical University Vienna, 4L, Waehringer Guertel 18-20, 1090, Vienna, Austria. thomas.beyer@meduniwien.ac.at.
3
Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
4
Department of Surgery, Surgical Research Laboratories, Medical University Vienna, Vienna, Austria.
5
CBmed - Center for Biomarker Research in Medicine (CBmed GmbH), Graz, Austria.
6
Institute of History and Ethics in Medicine, Technical University Munich, Munich, Germany.
7
Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria.
8
Division of Ahmanson Translational Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
9
Department of Pathology, Medical University Vienna, Vienna, Austria.
10
Department of Radiology, Eberhard Karls Universität Tübingen, Tübingen, Germany.
11
Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.
12
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
13
Department of Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
14
Department of Laboratory Animal Pathology, University of Veterinary Medicine, Vienna, Austria.
15
Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria.
16
University Medicine Greifswald, Institute for Ethics and History of Medicine, Greifswald, Germany.
17
Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
18
Werner Siemens Imaging Center, Department for Preclinical Imaging and Radiopharmacy, Eberhard Karls Universität Tübingen, Tübingen, Germany.
19
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner site, Tübingen, Germany.
20
Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
21
Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.
22
Averbis GmbH, Freiburg, Germany.
23
Isotope Technologies Garching GmbH, Garching, Germany.
24
Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna, Austria.
25
Centre for Health Economics, University of York, York, UK.
26
Diagnostic and Research Center for Molecular Biomedicine, Institute of Pathology, Medical University of Graz, Graz, Austria.
27
Institute of Pathology, Medical University of Graz, Graz, Austria.
28
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Abstract

Here, we report on the outcome of the 2nd International Danube Symposium on advanced biomarker development that was held in Vienna, Austria, in early 2018. During the meeting, cross-speciality participants assessed critical aspects of non-invasive, quantitative biomarker development in view of the need to expand our understanding of disease mechanisms and the definition of appropriate strategies both for molecular diagnostics and personalised therapies. More specifically, panelists addressed the main topics, including the current status of disease characterisation by means of non-invasive imaging, histopathology and liquid biopsies as well as strategies of gaining new understanding of disease formation, modulation and plasticity to large-scale molecular imaging as well as integrative multi-platform approaches. Highlights of the 2018 meeting included dedicated sessions on non-invasive disease characterisation, development of disease and therapeutic tailored biomarkers, standardisation and quality measures in biospecimens, new therapeutic approaches and socio-economic challenges of biomarker developments. The scientific programme was accompanied by a roundtable discussion on identification and implementation of sustainable strategies to address the educational needs in the rapidly evolving field of molecular diagnostics. The central theme that emanated from the 2nd Donau Symposium was the importance of the conceptualisation and implementation of a convergent approach towards a disease characterisation beyond lesion-counting "lumpology" for a cost-effective and patient-centric diagnosis, therapy planning, guidance and monitoring. This involves a judicious choice of diagnostic means, the adoption of clinical decision support systems and, above all, a new way of communication involving all stakeholders across modalities and specialities. Moreover, complex diseases require a comprehensive diagnosis by converging parameters from different disciplines, which will finally yield to a precise therapeutic guidance and outcome prediction. While it is attractive to focus on technical advances alone, it is important to develop a patient-centric approach, thus asking "What can we do with our expertise to help patients?"

KEYWORDS:

Biomarker; Ethics; Health economics; Liquid biopsies; Molecular and digital pathology; Molecular imaging; Omics technologies; Patient management; Pharmacology; Sample quality; Theranostics; Treatment

PMID:
31049831
DOI:
10.1007/s11307-019-01361-2

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center